CIK 0001806310 · Non-accelerated filer<br>Smaller reporting company
Taysha Gene Therapies, Inc.
Sign in to watch- Ticker
- TSHA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 843199512
- Phone
- (214) 612-0000
- Business address
- 3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS, TX, 75247
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 7 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-05-29 | Stalfort John A III Director | Grant or award | +49,220 | 1,098,601 | ||
| 2024-05-29 | Stalfort John A III Director | Grant or award · Stock Option (right to buy) | +98,440 | 98,440 | ||
| 2024-05-29 | Long Alison S Director | Grant or award | +49,220 | 49,220 | ||
| 2024-05-29 | Long Alison S Director | Grant or award · Stock Option (right to buy) | +98,440 | 98,440 | ||
| 2024-05-29 | Donenberg Phillip B. Director | Grant or award | +49,220 | 163,331 | ||
| 2024-05-29 | Donenberg Phillip B. Director | Grant or award · Stock Option (right to buy) | +98,440 | 98,440 | ||
| 2024-05-29 | Sepp-Lorenzino Laura Director | Grant or award | +49,220 | 49,220 | ||
| 2024-05-29 | Sepp-Lorenzino Laura Director | Grant or award · Stock Option (right to buy) | +98,440 | 98,440 | ||
| 2024-02-02 | Alam Kamran CHIEF FINANCIAL OFFICER | Shares withheld for taxes | −1,288 | $1.51 | $2K | 840,937 |
| 2024-01-02 | Alam Kamran Chief Financial Officer | Grant or award | +590,413 | 842,225 | ||
| 2024-01-02 | Alam Kamran Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +590,413 | 590,413 | ||
| 2024-01-02 | Nagendran Sukumar President and Head of R&D | Grant or award | +863,617 | 897,843 | ||
| 2024-01-02 | Nagendran Sukumar President and Head of R&D | Grant or award · Employee Stock Option (right to buy) | +863,617 | 863,617 | ||
| 2024-01-02 | Nolan Sean P. Chief Executive Officer | Grant or award | +1,184,688 | 1,185,858 | ||
| 2024-01-02 | Nolan Sean P. Chief Executive Officer | Grant or award · Employee Stock Option (right to buy) | +1,184,688 | 1,184,688 | ||
| 2023-12-14 | Alam Kamran Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +187,582 | 187,582 | ||
| 2023-12-14 | Nagendran Sukumar President and Head of R&D | Grant or award · Employee Stock Option (right to buy) | +334,005 | 334,005 | ||
| 2023-12-14 | Nolan Sean P. Chief Executive Officer | Grant or award · Employee Stock Option (right to buy) | +466,550 | 466,550 | ||
| 2023-11-17 | Manning Paul B 10% owner | Purchase | +100,000 | $1.63 | $163K | 16,566,667 |
| 2023-11-01 | Long Alison S Director | Grant or award · Stock Option (right to buy) | +43,800 | 43,800 |
Page 4 of 9 · 173 trades